Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (12): 1304-1309.DOI: 10.3969/j.issn.1673-8640.2020.12.025
Previous Articles Next Articles
BIE Lihan1, FANG Meng1, LU Zhicheng2, GAO Chunfang1
Received:
2020-03-04
Online:
2020-12-30
Published:
2020-12-31
CLC Number:
BIE Lihan, FANG Meng, LU Zhicheng, GAO Chunfang. Research progress of sialic acid markers in tumor occurrence and development[J]. Laboratory Medicine, 2020, 35(12): 1304-1309.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.12.025
[1] | MEREITER S,BALMAÑA M,CAMPOS D,et al. Glycosylation in the era of cancer-targeted therapy:where are we heading?[J]. Cancer Cell,2019,36(1):6-16. |
[2] | LI F,DING J.Sialylation is involved in cell fate decision during development,reprogramming and cancer progression[J]. Protein Cell,2019,10(8):550-565. |
[3] | COHEN M,VARKI A .The sialome-far more than the sum of its parts[J]. OMICS,2010,14(4):455-464. |
[4] | SCHAUER R,KAMERLING J P .Exploration of the sialic acid world[J]. Adv Carbohydr Chem Biochem,2018,75:1-213. |
[5] | PEARCE O M,LÄUBLI H. Sialic acids in cancer biology and immunity[J]. Glycobiology,2016,26(2):111-128. |
[6] | WATERS P J,LEWRY E,PENNOCK C A .Measurement of sialic acid in serum and urine:clinical applications and limitations[J]. Ann Clin Biochem,1992,29(Pt6):625-637. |
[7] | TESHIMA S,TAMAI K,HAYASHI Y,et al.New enzymatic determination of sialic acid in serum[J]. Clin Chem,1988,34(11):2291-2294. |
[8] | HORIUCHI T,KUROKAWA T.New enzymatic endpoint assay of serum sialic acid[J]. Clin Chim Acta,1989,182(1):117-121. |
[9] | KRISHNAN K,BALASUNDARAM S. Evaluation of total and lipid bound sialic acid in serum in oral leukoplakia[J]. J Clin Diagn Res,2017,11(3):ZC25-ZC27. |
[10] | TEWARSON S L,MITTAL V P,SINGH M,et al.Serum sialic acid-an important cancer marker[J]. Indian J Cancer,1993,30(3):125-131. |
[11] | RAJENDIRAN K S,ANANTHANARAYANAN P H,SATHEESH S,et al.Elevated levels of serum sialic acid and high-sensitivity C-reactive protein:markers of systemic inflammation in patients with chronic heart failure[J]. Br J Biomed Sci,2014,71(1):29-32. |
[12] | CANDIDO J,HAGEMANN T.Cancer-related inflammation[J]. J Clin Immunol,2013,33(Suppl 1):79-84. |
[13] | DE GRAAF T W,VAN DER STELT M E,ANBERGEN M G,et al. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein(orosomucoid) in human sera[J]. J Exp Med,1993,177(3):657-666. |
[14] | 邢卉春. 甲胎蛋白异质体检测在原发性肝癌诊疗中的价值[J]. 中华检验医学杂志,2013,36(2):123-124. |
[15] | OHYAMA C,HOSONO M,NITTA K,et al.Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy[J]. Glycobiology,2004,14(8):671-679. |
[16] | ISHIKAWA T,YONEYAMA T,TOBISAWA Y,et al.An automated micro-total immunoassay system for measuring cancer-associated α2,3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis[J]. Int J Mol Sci,2017,18(2):470. |
[17] | POON T C W,MOK T S K,CHAN A T C,et al. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein[J]. Clin Chem,2002,48(7):1021-1027. |
[18] | ANG I L,POON T C W,LAI P B S,et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma:a glycoproteomic approach[J]. J Proteome Res,2006,5(10):2691-2700. |
[19] | ZHANG Z,WUHRER M,HOLST S.Serum sialylation changes in cancer[J]. Glycoconj J,2018,35(2):139-160. |
[20] | ZENG P,LI H,CHEN Y,et al.Serum CA199 levels are significantly increased in patients suffering from liver,lung,and other diseases[J]. Prog Mol Biol Transl Sci,2019,162:253-264. |
[21] | LAN Y,HAO C,ZENG X,et al.Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers[J]. Am J Cancer Res,2016,6(11):2390-2415. |
[22] | SALDOVA R,ROYLE L,RADCLIFFE C M,et al.Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG[J]. Glycobiology,2007,17(12):1344-1356. |
[23] | MUNKLEY J .The role of sialyl-Tn in cancer[J]. Int J Mol Sci,2016,17(3):275. |
[24] | KRISHN S R,KAUR S,SMITH L M,et al.Mucins and associated glycan signatures in colon adenoma-carcinoma sequence:prospective pathological implication(s) for early diagnosis of colon cancer[J]. Cancer Lett,2016,374(2):304-314. |
[25] | SUNG P L,WEN K C,HORNG H C,et al.The role of α2,3-linked sialylation on clear cell type epithelial ovarian cancer[J]. Taiwan J Obstet Gynecol,2018,57(2):255-263. |
[26] | WU H,SHI X L,ZHANG H J,et al.Overexpression of ST3Gal-Ⅰ promotes migration and invasion of HCCLM3 in vitro and poor prognosis in human hepatocellular carcinoma[J]. Onco Targets Ther,2016,9:2227-2236. |
[27] | CUI H X,WANG H,WANG Y,et al.ST3Gal Ⅲ modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules[J].Oncol Rep,2016,36(6):3317-3324. |
[28] | MAJURI M L,NIEMELÄ R,TIISALA S,et al.Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines:role in synthesis of E-selectin counter-receptors[J]. Int J Cancer,1995,63(4):551-559. |
[29] | PÉREZ-GARAY M,ARTETA B,LLOP E,et al. α2,3-sialyltransferase ST3Gal Ⅳ promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues[J]. Int J Biochem Cell Biol,2013,45(8):1748-1757. |
[30] | SHEN L,LUO Z,WU J,et al.Enhanced expression of α2,3-linked sialic acids promotes gastric cancer cell metastasis and correlates with poor prognosis[J]. Int J Oncol,2017,50(4):1201-1210. |
[31] | YOSHIHAMA N,YAMAGUCHI K,CHIGITA S,et al.A novel function of CD82/KAI1 in sialyl Lewis antigen-mediated adhesion of cancer cells:evidence for an anti-metastasis effect by down-regulation of sialyl lewis antigens[J]. PLoS One,2015,10(4):e0124743. |
[32] | CHUNG T W,KIM S J,CHOI H J,et al.Hepatitis B virus X protein specially regulates the sialyl lewis a synthesis among glycosylation events for metastasis[J]. Mol Cancer,2014,13:222. |
[33] | GARNHAM R,SCOTT E,LIVERMORE K E,et al.ST6GAL1:a key player in cancer[J]. Oncol Lett,2019,18(2):983-989. |
[34] | SWINDALL A F,BELLIS S L.Sialylation of the fas death receptor by ST6Gal-I provides protection against fas-mediated apoptosis in colon carcinoma cells[J]. J Biol Chem,2011,286(26):22982-22990. |
[35] | IMAMAKI R,OGAWA K,KIZUKA Y,et al.Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis[J]. Oncogene,2018,37(31):4287-4299. |
[36] | HAN Y,LIU Y,FU X,et al.miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1[J]. J Physiol Biochem,2018,74(3):491-501. |
[37] | BRITAIN C M,HOLDBROOKS A T,ANDERSON J C,et al.Sialylation of EGFR by the ST6Gal-Ⅰ sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death[J]. J Ovarian Res,2018,11(1):12. |
[38] | CHANG T C,CHIN Y T,NANA A W,et al.Enhancement by nano-diamino-tetrac of antiproliferative action of gefitinib on colorectal cancer cells:mediation by EGFR sialylation and PI3K activation[J]. Horm Cancer,2018,9(6):420-432. |
[39] | LIU N,ZHU M,LINHAI Y,et al.Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways[J]. Oncol Rep,2018,40(5):2997-3005. |
[40] | OGAWA T,HIROHASHI Y,MURAI A,et al.ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway[J]. Oncotarget,2017,8(68):112550-112564. |
[41] | LIU B,LIU Y,ZHAO L,et al.Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway[J]. Mol Carcinog,2017,56(12):2669-2680. |
[42] | MUNKLEY J,OLTEAN S,VODÁK D,et al. The androgen receptor controls expression of the cancer- associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer[J]. Oncotarget,2015,6(33):34358-34374. |
[43] | BOS P D,ZHANG X H,NADAL C,et al.Genes that mediate breast cancer metastasis to the brain[J]. Nature,2009,459(7249):1005-1009. |
[44] | FALCONER R A,ERRINGTON R J,SHNYDER S D,et al.Polysialyltransferase:a new target in metastatic cancer[J]. Curr Cancer Drug Targets,2012,12(8):925-939. |
[45] | GONG L,ZHOU X,YANG J,et al.Effects of the regulation of polysialyltransferase ST8SiaⅡ on the invasiveness and metastasis of small cell lung cancer cells[J]. Oncol Rep,2017,37(1):131-138. |
[46] | LIU J,ZHENG X,PANG X,et al.Ganglioside GD3 synthase(GD3S),a novel cancer drug target[J]. Acta Pharm Sin B,2018,8(5):713-720. |
[47] | NGUYEN K,YAN Y,YUAN B,et al.ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway[J]. Mol Cancer Ther,2018,17(12):2689-2701. |
[48] | BOBOWSKI M,VINCENT A,STEENACKERS A,et al.Estradiol represses the G(D3),synthase gene,ST8SIA1,expression in human breast cancer cells by preventing NFκB binding to,ST8SIA1,promoter[J]. PLoS One,2013,8(4):e62559. |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854. |
[3] | DING Xiaoyuan, DAI Jinsheng, JIAO Ronghong, MA Suli, ZHU Haifeng, WU Mengya, CHE Yanran, ZHANG Lei. Influence of obesity/overweight on inflammatory factors of Th1/Th2 and Th17/Treg in children with asthma attacks [J]. Laboratory Medicine, 2023, 38(8): 748-752. |
[4] | ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418. |
[5] | GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306. |
[6] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[7] | WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195. |
[8] | QIAN Linyu, LIANG Weifang, TANG Sichen. Determination and clinical significance of NLRP3,CTRP6 and IL-1β in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2023, 38(10): 936-940. |
[9] | WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99. |
[10] | KONG Yujie, WANG Chen, HE Bing. Research progress of N6-methyladenosine in biological function and detection technology [J]. Laboratory Medicine, 2022, 37(9): 872-876. |
[11] | WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881. |
[12] | LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740. |
[13] | WEN Shuzhan, FU Zile, CHEN Shuying. Expression and bioinformatics analysis of hsa-miR-34a in tumors [J]. Laboratory Medicine, 2022, 37(7): 657-663. |
[14] | GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine:from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312. |
[15] | ZHAI Shana, SUN Qinghai, YU Yongwu, YE Fang, LIU Maodong. Influence of vancomycin combined with meropenem on serum TNF-α,PCT,IL-6 and peritoneal fluid WBC count in PDRP patients [J]. Laboratory Medicine, 2022, 37(4): 360-364. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||